Gene therapy and radiation for intermediate-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new gene therapy (aglatimagene besadenovec) given as an injection into the prostate before standard radiation therapy for men with intermediate-risk prostate cancer. The goal is to see if adding this treatment can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer that has not spread beyond the prostate and is considered 'intermediate risk' by your doctor.
- You are planning to receive radiation therapy to the prostate only (not the whole pelvis).
- You are not currently taking high-dose steroids or other immune-suppressing drugs.
- You do not have active liver disease like cirrhosis or hepatitis.
- You have not had prior treatment for prostate cancer, except possibly a TURP procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of focused radiation therapy for men with intermediate or high-risk prostate cancer that hasn't spread. It aims to improve outcomes by targeting the main tumor seen on MRI.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This Phase 1/2 study tests whether adding a cancer-targeting gene therapy (HSV-tk) and the antiviral medicine valacyclovir to brachytherapy can better treat recurrent prostate cancer in the prostate area. It may help by making cancer cells more vulnerable to the treatment.
This trial tests whether combining standard hormone therapy and radiation with a special targeted radiation (PSMA-targeted radiotherapy) is safe and effective for men with high-risk prostate cancer that hasn't spread outside the pelvis.
This trial studies a type of focused radiation (“ablative radiotherapy”) for prostate tumors considered intermediate- or high-risk. It may help improve control of the cancer while aiming for acceptable side effects.
Hear when a new Prostate Cancer Patients Treated by Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.